首页> 美国卫生研究院文献>British Journal of Cancer >Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+ HER2− advanced breast cancer: results from BOLERO-2

【2h】

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+ HER2− advanced breast cancer: results from BOLERO-2

机译：无细胞DNA中PIK3CA突变与依维莫司在HR +HER2−晚期乳腺癌中的疗效之间的相关性：BOLERO-2的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation.

机译：背景：目前的分析是使用患者随机分组时收集的血浆样品中的无细胞DNA（cfDNA）进行的，以评估PIK3CA热点突变对BOLERO-2参与者依维莫司疗效的影响。

著录项

期刊名称 British Journal of Cancer
作者
Mary Ellen Moynahan; David Chen; Wei He; Patricia Sung; Aliaksandra Samoila; Daoqi You; Trusha Bhatt; Parul Patel; Francois Ringeisen; Gabriel N Hortobagyi; Jose Baselga; Sarat Chandarlapaty;
展开▼
作者单位

展开▼
年(卷),期 2017(116),6
年度 2017
页码 726–730
总页数 5
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
BOLERO-2 PIK3CA cfDNA everolimus HRsup+/sup breast cancer;

机译：BOLERO-2;PIK3CA;cfDNA;依维莫司;HR sup + / sup乳腺癌;

相似文献

外文文献
中文文献
专利

1. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR|[plus]|, HER2|[minus]| advanced breast cancer: results from BOLERO-2 [J] . Mary EllenMoynahan, DavidChen, WeiHe, British Journal of Cancer . 2017,第6期

机译：无细胞DNA中PIK3CA突变与依维莫司在HR | [|||，HER2 | [-] |]中的功效之间的相关性晚期乳腺癌：BOLERO-2的结果
2. Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2 [J] . BeckJ.T., HortobagyiG.N., CamponeM., Breast cancer research and treatment. . 2014,第3期

机译：依维莫司联合依西美坦作为HR +，HER2晚期BOLERO-2乳腺癌的一线治疗
3. A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2-breast cancer patients using an FDA RT-PCR cleared test [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：对社区环境中Pik3CA突变的大型研究鉴定了使用FDA RT-PCR清除试验在高级HR +，Her2-乳腺癌患者中跨年龄组的变化阳性率的变化阳性率
4. Correlation Analysis between PIK3CA, TP53, CDH1 Genes Mutations and Breast Cancer [C] . Dongyue Zhu, Yunjing Gu, Ping Zhu International Symposium on Distributed Computing and Applications for Business Engineering and Science . 2018

机译：PIK3CA，TP53，CDH1基因突变与乳腺癌的相关性分析
5. Modeling HER2 Mutations in Colorectal Cancer Using a HER2 Transgenic Mouse Model and Gastrointestinal Organoids [D] . Murray, Elisa. 2020

机译：使用HER2转基因小鼠模型和胃肠有机体在结肠直肠癌中建模HER2突变
6. Everolimus plus exemestane as first-line therapy in HR+ HER2− advanced breast cancer in BOLERO-2 [O] . J. Thaddeus Beck, Gabriel N. Hortobagyi, Mario Campone, -1

机译：依维莫司+依西美坦作为HR +HER2−晚期BOLERO-2乳腺癌的一线治疗
7. 163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC) [O] . E.M. Ciruelos, T. Delea, A. Moynahan, 2020

机译：163P人口调整的太阳能-1和Bolero-2的比较：PFS与二线alpelisib +富勒斯特语+ Everolimus + Extemestane在绝经后PTS，PIK3CA-MUT激素受体阳性（HR +）人体表皮生长因子受体-2阴性（HER2 - ）晚期乳腺癌（ABC）

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+ HER2− advanced breast cancer: results from BOLERO-2

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅